PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15121897-7	2004	The daunomycin-conjugated TFO inhibited transcription in vitro and reduced c-myc promoter activity in prostate and breast cancer cells.	Daunorubicin	4-14	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	75-80	
33071281-11	2020	Finally, in an AML xenograft model administration of DNR or the P2X7R antagonist, AZ10606120 significantly reduced leukemic growth and coadministration of the drugs proved more efficacious than single treatment as it reduced both P2X7RA and P2X7RB levels and downmodulated c-myc oncogene.	Daunorubicin	53-56	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	273-278	
33967147-8	2021	After the standard induction therapy with daunorubicin and cytarabine, the number of myeloblasts in the bone marrow decreased, and the amplified MYC signals disappeared.	Daunorubicin	42-54	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	145-148	
16449206-0	2006	Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.	Daunorubicin	43-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	112-117	
15121897-0	2004	DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.	Daunorubicin	39-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	132-137	
15121897-4	2004	The 11mer daunomycin-conjugated GT (dauno-GT11) TFO targeted a sequence upstream of the P2 promoter, a site known to be critical for transcription of the c-myc gene.	Daunorubicin	10-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	154-159	
11441001-6	2001	Similar results were obtained by increased endogenous ceramide levels in response to nontoxic concentrations of daunorubicin, resulting in the inhibition of telomerase and c-Myc activities.	Daunorubicin	112-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	172-177